Ascletis Pharma Inc
HKEX:1672

Watchlist Manager
Ascletis Pharma Inc Logo
Ascletis Pharma Inc
HKEX:1672
Watchlist
Price: 1.6 HKD -5.33%
Market Cap: 1.6B HKD
Have any thoughts about
Ascletis Pharma Inc?
Write Note

Ascletis Pharma Inc
Minority Interest

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Ascletis Pharma Inc
Minority Interest Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Minority Interest CAGR 3Y CAGR 5Y CAGR 10Y
Ascletis Pharma Inc
HKEX:1672
Minority Interest
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Beigene Ltd
HKEX:6160
Minority Interest
ÂĄ0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Akeso Inc
HKEX:9926
Minority Interest
-ÂĄ87.6m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Minority Interest
ÂĄ183.1m
CAGR 3-Years
90%
CAGR 5-Years
55%
CAGR 10-Years
N/A
Shanghai RAAS Blood Products Co Ltd
SZSE:002252
Minority Interest
ÂĄ14.2m
CAGR 3-Years
39%
CAGR 5-Years
2%
CAGR 10-Years
0%
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
Minority Interest
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Ascletis Pharma Inc
Glance View

Market Cap
1.6B HKD
Industry
Biotechnology

Ascletis Pharma, Inc. operates as biotechnology firm to test the waters. The company is headquartered in Hangzhou, Zhejiang and currently employs 266 full-time employees. The company went IPO on 2018-08-01. The firm is focused on three therapeutic areas, including anti-viral, cancer and fatty liver disease. The Company’s main products include drugs against hepatitis C virus (HCV), human immunodeficiency virus (HIV) and hepatitis B virus (HBV).

Intrinsic Value
0.7 HKD
Overvaluation 56%
Intrinsic Value
Price

See Also

Back to Top